Clinical Trial Update: Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update for Naxitamab (hu3F8) in pediatric high-risk or refractory/recurrent neuroblastoma (NCT06013618) is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• Naxitamab (hu3F8) (naxitamab)

Snippet

Sponsor: Sun Yat-Sen University Cancer Center | Conditions: Neuroblastoma | Phase 2 | Status: RECRUITING